Jessica H Taylor,Hannah M Gunter,David W Haas et al.
Jessica H Taylor et al.
Advances in antiretroviral drug development have led to safer drugs with improved tolerability, enhanced activity against drug-resistant HIV, higher genetic barrier to resistance, and fewer drug-drug interactions. Genetic polymorphisms in d...
Prioritizing drugs for future clinical pharmacogenomics studies in Saudi Arabia: a generalizable multi-criteria framework [0.03%]
在沙特阿拉伯的未来临床药物基因组学研究中优先考虑药物：一个可推广的多标准框架
Mustafa Adnan Malki
Mustafa Adnan Malki
Aims: Despite over 400 high-evidence drug-gene associations in pharmacogenomic (PGx) guidelines and drug labels, prioritizing drugs for clinical PGx research remains challenging when local outcome data are limited. In Sau...
Pharmacogenetics of venlafaxine response in older adults with depression and chronic lower back pain [0.03%]
老年抑郁症和慢性下背痛患者对文拉法辛的药物基因组学研究
Martin Kronenbuerger,Leen Magarbeh,Stefan Kloiber et al.
Martin Kronenbuerger et al.
Background: Late-life depression (LLD) and chronic low back pain frequently co-occur and exacerbate one another. Outcomes with antidepressant treatment in this population are often suboptimal. Pharmacogenetic factors may ...
The use of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) to guide treatment selection in metastatic breast cancer [0.03%]
循环肿瘤DNA在转移性乳腺癌治疗选择中的作用
Oluwaferanmi Bello,Olivia Rieur,Neelima Vidula
Oluwaferanmi Bello
Metastatic breast cancer is a heterogeneous disease entity with varying genomic alterations. Mutations may be acquired through tumor evolution under the pressure of treatment. While both tumor tissue genotyping and cell-free DNA (cfDNA)/cir...
Marianna Danielli,Nicole Benfield,Helen R Warren et al.
Marianna Danielli et al.
Pharmacogenomics (PGX) offers a key route to individualizing cardiovascular therapy, with robust evidence now supporting genotype-guided prescribing for commonly prescribed cardiovascular drugs, such as antiplatelets, -beta-blockers, statin...
Acute hemolytic anemia and methemoglobinemia in a pediatric oncology patient with G6PD deficiency: a case report [0.03%]
G6PD缺乏的儿科肿瘤患者出现急性溶血性贫血和高铁血红蛋白血症的病例报告
Chaja N Klein,Monique H Suijker,Katja M J Heitink-Pollé et al.
Chaja N Klein et al.
Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzymatic disorder that is often asymptomatic until exposure to oxidative stress, such as certain medications. Rasburicase, used for tumor lysis ...
CYP2C:TG haplotype in Ecuador and Nicaragua: insights into CYP2C19 genotype-phenotype correlation in context to Mestizo populations [0.03%]
厄瓜多尔和尼加拉瓜的CYP2C:TG单体型：混血人群中与CYP2C19基因型表型关联的新见解
Carla González de la Cruz,Catalina Altamirano-Tinoco,Juan Antonio Villatoro-García et al.
Carla González de la Cruz et al.
Aim: The impact of the CYP2C:TG haplotype on CYP2C19-mediated omeprazole metabolism was evaluated. Patients and methods: CYP2C19 enzyma...
The 8th European Society of Pharmacogenomics and Personalized Therapy (ESPT) congress [0.03%]
欧洲药物基因组学和个性化治疗学会（ESPGT）第八届年会
Ron H N van Schaik,Jesse J Swen,Adrián Llerena et al.
Ron H N van Schaik et al.
On November 5-8, 2025, the European Society of Pharmacogenomics and Personalized Therapy (ESPT) organized its 8th biennial congress, this time in Rotterdam, The Netherlands (www.esptcongress.org). The congress aimed to address the current s...
Antiplatelet therapy in high-bleeding risk patients with acute coronary syndrome: pharmacogenomics in the era of precision medicine [0.03%]
急性冠状动脉综合征高出血风险患者抗血小板治疗的药理基因组学与精准医学时代的个体化医疗
Nikolaos Michailidis,Myria Pallikarou,Vangelis G Manolopoulos et al.
Nikolaos Michailidis et al.
The management of high-bleeding risk (HBR) patients undergoing percutaneous coronary intervention (PCI) for an acute coronary syndrome (ACS) remains a significant challenge, requiring careful balancing of ischemic prevention and bleeding av...
Hana Al Alshaykh,Emily Cicali,Larisa H Cavallari et al.
Hana Al Alshaykh et al.
Aim: Assess the acceptance of genotype-based pharmacist recommendations made within a pharmacogenetics (PGx) clinic. Methods: Patients ...